XML 26 R12.htm IDEA: XBRL DOCUMENT v3.19.2
Debt
6 Months Ended
Jun. 30, 2019
Debt Disclosure [Abstract]  
Debt
6. Debt
 
The table below reflects the Company's total debt, including borrowings under its credit agreement and master loan agreements for equipment notes:
 
 
 
 
 
Stated Interest
 
Payment
 
Term
 
 
Outstanding

Balance as of

June 30,
 
 
Outstanding

Balance as of

December 31,
 
(dollar amounts in thousands)
 
Inception Date
 
Rate (per annum)
 
Frequency
 
(years)
 
 
2019
 
 
2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Credit Agreement
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revolving loans
 
6/30/2016
 
 
Variable
 
Variable
 
 
5
 
 
$
52,410
 
 
$
58,306
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Equipment Notes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Equipment Note 1
 
9/28/2018
 
 
4.16%
 
Semi-annual
 
 
5
 
 
 
11,734
 
 
 
12,655
 
Equipment Note 2
 
9/28/2018
 
 
4.23%
 
Semi-annual
 
 
7
 
 
 
11,745
 
 
 
12,279
 
Equipment Note 3
 
12/31/2018
 
 
3.97%
 
Semi-annual
 
 
5
 
 
 
2,291
 
 
 
2,291
 
Equipment Note 4
 
12/31/2018
 
 
4.02%
 
Semi-annual
 
 
7
 
 
 
2,313
 
 
 
2,313
 
Equipment Note 5
 
12/31/2018
 
 
4.01%
 
Semi-annual
 
 
7
 
 
 
1,948
 
 
 
1,948
 
Equipment Note 6
 
6/25/2019
 
 
2.89%
 
Semi-annual
 
 
7
 
 
 
15,005
 
 
 
 
Equipment Note 7
 
6/24/2019
 
 
3.09%
 
Semi-annual
 
 
5
 
 
 
9,033
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
54,069
 
 
 
31,486
 
Total debt
 
 
 
 
 
 
 
 
 
 
 
 
 
106,479
 
 
 
89,792
 
Less: current portion of long-term debt
 
 
 
 
 
 
 
 
 
 
 
 
 
(6,856
)
 
 
(3,681
)
Long-term debt
 
 
 
 
 
 
 
 
 
 
 
 
$
99,623
 
 
$
86,111
 
 
Credit Agreement
 
On June 30, 2016, the Company entered into a five-year amended and restated credit agreement as amended from time to time, (the “Credit Agreement”) with a syndicate of banks led by JPMorgan Chase Bank, N.A. and Bank of America, N.A, that provided for a $250 million facility (the “Facility”), which could be used for revolving loans and letters of credit. On September 28, 2018, the Company amended the Credit Agreement. This amendment, among other things, reduced the amount of the Facility available to be used for letters of credit to a maximum of $150 million. The Facility also allows for revolving loans and letters of credit in Canadian dollars and other currencies, up to the U.S. dollar equivalent of $50 million. The Company has an expansion option to increase the commitments under the Facility or enter into incremental term loans, subject to certain conditions, by up to an additional $100 million upon receipt of additional commitments from new or existing lenders. Subject to certain exceptions, the Facility is secured by substantially all of the assets of the Company and its domestic subsidiaries, and by a pledge of substantially all of the capital stock of the Company’s domestic subsidiaries and 65% of the capital stock of the direct foreign subsidiaries of the Company. Additionally, subject to certain exceptions, the Company’s domestic subsidiaries also guarantee the repayment of all amounts due under the Credit Agreement. If an event of default occurs and is continuing, on the terms and subject to the conditions set forth in the Credit Agreement, amounts outstanding under the Facility may be accelerated and may become or be declared immediately due and payable. Borrowings under the Credit Agreement are used for working capital, capital expenditures, acquisitions, stock repurchases and other general corporate purposes.
 
Amounts borrowed under the Credit Agreement bear interest, at the Company’s option, at a rate equal to either (1) the Alternate Base Rate (as defined in the Credit Agreement), plus an applicable margin ranging from 0.00% to 1.00%; or (2) Adjusted LIBO Rate (as defined in the Credit Agreement) plus an applicable margin ranging from 1.00% to 2.00%. The applicable margin is determined based on the Company’s consolidated leverage ratio (the “Leverage Ratio”) which is defined in the Credit Agreement as Consolidated Total Indebtedness divided by Consolidated EBITDA (as defined in the Credit Agreement). Letters of credit issued under the Facility are subject to a letter of credit fee of 1.125% to 2.125% for non-performance letters of credit or 0.625% to 1.125% for performance letters of credit, based on the Company’s consolidated Leverage Ratio. The Company is subject to a commitment fee of 0.20% to 0.375%, based on the Company’s consolidated Leverage Ratio, on any unused portion of the Facility. The Credit Agreement restricts certain types of payments when the Company’s consolidated Leverage Ratio exceeds 2.25. The weighted average interest rate on borrowings outstanding on the Facility for the six months ended June 30, 2019 was 3.51% per annum.
 
Under the Credit Agreement, the Company is subject to certain financial covenants and must maintain a maximum consolidated Leverage Ratio of 3.0 and a minimum interest coverage ratio of 3.0, which is defined in the Credit Agreement as Consolidated EBITDA (as defined in the Credit Agreement) divided by interest expense (as defined in the Credit Agreement). The Credit Agreement also contains covenants including limitations on asset sales, investments, indebtedness and liens. In connection with any permitted acquisition where the total consideration exceeds $50 million, the Company may request that the maximum permitted consolidated Leverage Ratio increase from 3.0 to 3.5. Any such increase shall begin in the quarter in which such permitted acquisition is consummated and shall continue in effect for four consecutive fiscal quarters. The Company was in compliance with all of its financial covenants under the Credit Agreement as of June 30, 2019.
 
As of June 30, 2019, the Company had letters of credit outstanding under the Facility of approximately $22.1 million, including $18.5 million related to the Company’s payment obligation under its insurance programs and approximately $3.6 million related to contract performance obligations.  
 
As of December 31, 2018, the Company had letters of credit outstanding under the Facility of approximately $21.2 million, including $17.6 million related to the Company’s payment obligation under its insurance programs and approximately $3.6 million related to contract performance obligations.
 
The Company had remaining deferred debt issuance costs totaling $0.5 million as of June 30, 2019, related to the line of credit. As permitted under ASU No. 2015-15, debt issuance costs have been deferred and are presented as an asset within other assets, which is amortized as interest expense over the term of the line of credit.
 
Equipment Notes
 
The Company has entered into Master Equipment Loan and Security Agreements (the “Master Loan Agreements”) with multiple banks. The Master Loan Agreements may be used for the financing of equipment between the Company and the lending banks pursuant to one or more equipment notes ("Equipment Note"). Each Equipment Note executed under the Master Loan Agreements constitutes a separate, distinct and independent financing of equipment and a contractual obligation of the Company, which may contain prepayment clauses.
 
As of
June 30, 2019
, the Company had seven Equipment Notes outstanding under the Master Loan Agreements that are collateralized by equipment and vehicles owned by the
Company. The following table sets forth our remaining principal payments for the Company’s outstanding Equipment Notes as of June 30, 2019:
 
 
 
Future
 
 
 
Equipment Notes
 
(In thousands)
 
Principal Payments
 
 
 
 
 
Remainder of 2019
 
$
3,581
 
2020
 
 
6,608
 
2021
 
 
6,852
 
2022
 
 
7,107
 
2023
 
 
10,360
 
2024
 
 
5,964
 
Thereafter
 
 
13,597
 
Total future principal payments
 
$
54,069
 
Less: current portion of equipment notes
 
 
(6,856
)
Long-term principal obligations
 
$
47,213